[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344507-105":59,"doc-detail-344507-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","considerations-for-using-potential-surrogate-endpoints-in-cancer-screening-trials","Considerations for using potential surrogate endpoints in cancer screening trials","","The requirement for large-scale, costly cancer screening trials spanning decades creates major barriers to developing, commercialising, and implementing new screening tests. One approach is to use surrogate endpoints at earlier timepoints instead of the ultimate endpoint of cancer mortality. This Review highlights key issues in selecting and using surrogate endpoints for cancer screening trials, proposes criteria for when and how such endpoints may be used, and suggests potential candidate endpoints. It also outlines the current landscape, challenges, and lessons from therapeutic trial settings, while noting the difficulty of validating surrogates even with well-designed studies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/considerations-for-using-potential-surrogate-endpoints-in-cancer-screening-trials/344507/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/considerations-for-using-potential-surrogate-endpoints-in-cancer-screening-trials/344507.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are surrogate endpoints considered in cancer screening trials?","Question",{"text":112,"@type":113},"Large, expensive trials over decades hinder development and implementation of new screening tests. Surrogate endpoints can provide earlier signals than cancer mortality at later timepoints.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the ultimate endpoint of interest discussed in the Review?",{"text":117,"@type":113},"The ultimate endpoint is cancer mortality, which is traditionally evaluated using outcomes that demonstrate population benefit.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is validating a surrogate endpoint challenging?",{"text":121,"@type":113},"Validation is extremely difficult even when clinical studies are carefully designed, because the surrogate must reliably support the ultimate clinical outcome and meet research and regulatory expectations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344507,1790198174,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Europe PMC unders uthManuscripts Europe M eC und Author Manuscripts  \nEurope PMC Funders Group  \nAuthor Manuscript  \nLancet Oncol. Author manuscript; available in PMC 2024 June 24.  \nPublished in final edited form as:  \nLancet Oncol. 2024 May 01; 25(5): e183–e192 . doi:10.1016/S1470-2045(24)00015-9 .  \nConsiderations for using potential surrogate endpoints in cancer screening trials  \nAlexis B Webb, PhD,  \nCancer Research UK, London, UK  \nChristine D Berg, MD,  \nEarly Cancer Detection Consultant, Bethesda, MD, USA  \nPhilip E Castle, PhD,  \nDivision of Cancer Prevention and Division of Cancer Epidemiology and Genetics, US National Cancer Institute, Rockville, MD, USA  \nDavid Crosby, PhD,  \nCancer Research UK, London, UK  \nProf Ruth Etzioni, PhD,  \nPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA  \nProf Larry G Kessler, ScD,  \nDepartment of Health Systems and Population Health (HSPOP), School of Public Health, University of Washington, Seattle, WA, USA  \nProf Usha Menon, FRCOG,  \nThis work is licensed under a BY 4.0 International license.  \nCorrespondence to: Peter D Sasieni.  \nCorrespondence to: Prof Peter D Sasieni, Wolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, [UK p.sasieni@qmul.ac.uk](UK p.sasieni@qmul.ac.uk).  \nContributors  \nAll authors conceived the study, searched the literature, contributed to the figures, and wrote, reviewed, and edited the draft. ABW, DC, UM, LGK, and PDS designed the figures and tables.  \nDeclaration of interests  \nCDB receives consultation fees from Mercy BioAnalytics, Lucid Diagnostics, and Medial Early Sign; and is the Chair of the Independent Data Monitoring Committee of the NHS Galleri Study for GRAIL. DC receives consultation fees from MD Anderson Cancer Center, the São Paulo Research Foundation, and Roche; and received payment or honoraria for lectures with EIT Health and the MD Anderson Cancer Center. UM had stock ownership (2011–21) awarded by University College London in Abcodia, which held the licence for the Risk of Ovarian Cancer Algorithm; reports research collaboration contracts with Cambridge University, QIMR Berghofer Medical Research Institute, Intelligent Lab on Fiber, RNA Guardian, Micronoma, MercyBio Analytics, Imperial College London, University of Innsbruck, and Dana Farber USA; received grant funding from the Medical Research Council (MRC) core funding awards MC_UU_ 00004/01 and MC_UU_ 00004/02, MRC Proximity to Discovery Industrial Connectivity Award, Cancer Research UK, the National Institute for Health Research (NIHR) HTA award 16/46/01, NIHR Biomedical Research Centre to University College London Hospitals, The Eve Appeal, the Australian National Health and Medical Research Council, Abcodia, India Alliance, Innovate UK grant, and various research collaborations; has a patent (EP10178345.4) for Breast Cancer Diagnostics; and is a member of Tina’s Wish Scientific Advisory Board (USA) and Research Advisory Panel, and Yorkshire Cancer Research (UK) . PDS holds grants for the GRAIL NHS Galleri multi-cancer screening study, Cancer Research UK and National Institute of Research BEST4 oesophageal screening trial, and the Yorkshire Cancer Research YORKSURe bladder screening trial; receives consulting fees from GRAIL on its scientific advisory board; is a member of advisory boards for NIHR ARTISTIC-3 (HPV testing in cervical screening), IARC ESTMAPA (triage in cervical screening), and the Yorkshire Cancer Research Yorkshire Lung Screening Trial; is the Chair of the National Cancer Research Institute Screening, Prevention & Early Diagnosis Group; and is the Chair of the NHS England Lung Cancer Screening Group, Cytosponge Implementations Group, and MCED Implementation Group. RE is supported by the National Cancer Institute (grant R35CA274442) . PEC, LGK, MP, RJCS, and ABW declare no competing interests.  \nEurope PMC unders uthManuscripts Europe M eC und Author Manuscripts  \nWebb et al. Page 2  \nMedica","cbCaims7YaonsbjI","https://ap.wps.com/l/cbCaims7YaonsbjI","pdf",364615,"English","# Abstract\n# Introduction","[{\"question\":\"Why are surrogate endpoints considered in cancer screening trials?\",\"answer\":\"Large, expensive trials over decades hinder development and implementation of new screening tests. Surrogate endpoints can provide earlier signals than cancer mortality at later timepoints.\"},{\"question\":\"What is the ultimate endpoint of interest discussed in the Review?\",\"answer\":\"The ultimate endpoint is cancer mortality, which is traditionally evaluated using outcomes that demonstrate population benefit.\"},{\"question\":\"Why is validating a surrogate endpoint challenging?\",\"answer\":\"Validation is extremely difficult even when clinical studies are carefully designed, because the surrogate must reliably support the ultimate clinical outcome and meet research and regulatory expectations.\"}]","Considerations for using potential surrogate endpoints in cancer screening trials | PDF",1790054168,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d115fdcc17b9b6285af8aafa877963fc.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5bb011800d92fbcb5647b2a6f8585c6.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca95dd3b733cd2634d7db3f2b71f00d5.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c75a36b9db0598cb1ac52c43762203d4.webp",980,1268]